- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial
© Oliveira et al.; licensee BioMed Central Ltd. 2012
Received: 24 November 2011
Accepted: 14 June 2012
Published: 20 June 2012
Renal evaluation studies are rare in American Cutaneous Leishmaniasis (ACL). The aim of this study is to investigate whether specific treatment reverts ACL-associated renal dysfunction.
A prospective study was conducted with 37 patients with ACL. Urinary concentrating and acidification ability was assessed before and after treatment with pentavalent antimonial.
The patients mean age was 35.6 ± 12 years and 19 were male. Before treatment, urinary concentrating defect (U/Posm <2.8) was identified in 27 patients (77%) and urinary acidification defect in 17 patients (46%). No significant glomerular dysfunction was observed before and after specific ACL treatment. There was no reversion of urinary concentrating defects, being observed in 77% of the patients before and in 88% after treatment (p = 0.344). Urinary acidification defect was corrected in 9 patients after treatment, reducing its prevalence from 40% before to only 16% after treament, (p = 0.012). Microalbuminuria higher than 30 mg/g was found in 35% of patients before treatment and in only 8% after treatment. Regarding fractional excretion of sodium, potassium, calcium, phosphorus and magnesium, there was no significant difference between pre and post-treatment period.
As previously described, urinary concentrating and acidification defects were found in an important number of patients with ACL. Present results demonstrate that only some patients recover urinary acidification capacity, while no one returned to normal urinary concentration capacity.
It is estimated that 1.5 to 2 million people develop symptomatic disease each year . American Cutaneous Leishmaniasis (ACL) is endemic in some countries in Africa, Middle East, Europe and Latin America, representing a Public Health problem, not only due to its high incidence, but also due to its potential to cause destructive and incapacitating lesions, with high psychosocial impact [4, 6].
Renal involvement has been described in visceral leishmaniasis (kala-azar), including from mild urinary abnormalities to severe glomerular involvement and renal failure [7–10]. Renal failure in kala-azar is thought to occur due to interstitial nephritis secondary to immune complex deposition and hypersensitivity to pentavalent antimonials [6, 11–13]. Tubular dysfunction has also been described in kala-azar as urinary concentrating and acidification defects, with few clinical manifestations .
In ACL there are very few studies regarding renal function evaluation, and the renal abnormalities described are linked to specific treatment with pentavalent antimonials . These drugs are described to cause acute kidney injury due to hypersensitivity reaction . Other possible mechanisms for kidney injury in ACL have not been investigated by now.
A recent study conducted by our study group found important abnormalities in ACL. Expression of the Na+/H+ exchanger (NHE3), H+-ATPase, and pendrin were all significantly higher in patients with ACL when compared with normal subjects. A combined urinary concentration and acidification defect was found in 32.4% of patients, before specific ACL treatment .
The aim of this study is to investigate if these tubular abnormalities persist after specific ACL-treatment.
This is a prospective study with 37 patients with confirmed diagnosis of ACL (epidemiologic, clinical and laboratorial) in a public health service in the city of Barbalha, Ceara, Brazil, between July 2008 and July 2009. Exclusion criteria was patients under 15 years-old or older than 60 years, use of pentavalent antimonials in the last 30 days, hypertension (Systolic blood pressure ≥ 140 or Diastolic blood pressure ≥ 90 mmHg), diabetes mellitus, urinary tract infection, systemic lupus erythematosus and other colagenosis, and previous kidney disease. The 37 patients were compared with 10 healthy volunteers. The protocol of this study was revised and approved by the Ethical Comitee of the Walter Cantidio University Hospital, Federal University of Ceara, Fortaleza, Brazil. Patients were included in the study after signing the informed consent form.
Diagnosis of ACL
Diagnosis of ACL was based on epidemiologic and clinical criteria, Montenegro skin test and identification of parasite in tissue biopsy.
Clinical and laboratory parameters
At the time of medical consult all symptoms and signals were evaluated, as well as race, age, gender, previous chronic diseases, number of skin lesions, time of disease, use of drugs, body mass index, blood pressure, Montenegro skin test, ACL classification. The following laboratory tests were studied in blood and plasma: urea (PUr), creatinine (PCr),pH, (Posm) osmolality, bicarbonate (BICs), sodium (PNa+), potassium (PK+), chloride (PCl-), magnesium (PMg++), calcium (PCa++), phosphorus (PP-), albumin/globulin, amilase, fast glucose, erythrocyte sedimentation rate (ESR). In urine were studied the following tests: creatinine and urea (UCr e UUr), sodium (UNa+), potassium (UK+), chloride (UCl-), calcium (UCa++), phosphorus (UP-), magnesium (UMg++), microalbuminuria, urinalysis, osmolality (Uosm) and pH (UpH).
Renal function evaluation
Glomerular filtration rate (GFR) was estimated through the Cockroft & Gault formula and it was considered abnormal when ≤ 90 ml/min/1,73 Body Surface Area m2. In an isolated urine sample collected before concentration and acidification tests, pre- and post-glucantime treatment sodium, potassium, chloride, magnesium and microalbuminuria were measured.
All patients underwent food and water deprivation for 12 hours. Fraction excretion of sodium (FENa), potassium (FEk), calcium (FECa), phosphorus (FEP), magnesium (FEMg) were calculated by standard formula. Microalbuminuria was measured in an isolated urine sample and normalized by urinary creatinine.
Urinary concentration ability was evaluated through the ratio between urinary and serum osmolality (U/Posm) after 12 hours water deprivation, and urinary osmolality (Uosm) was measured before and 4 hours after administration of intranasal DDAVP® (desmopressin acetate 20mcg/kg - T0 and T4). Urinary acidification was evaluated by the urinary pH before and after administration of oral CaCl2 2 mEq/kg (T0 and T4). Acidification defect was determined by the inability in decreasing UpH for less than 5.50.
All patients underwent standard treatment with antimonial (Glucantime®) in the dose of 20 mg/kg/day for 20 days. All tests were done before treatment and 4 weeks after the beginning of the treatment.
Pre-glucantime group – Tests performed before the beginning of treatment.
Post-glucantime group – Tests performed 4 weeks after the beginning of the treatment.
Urea: Determined by colorimetric uricase method (Labtest®). The results were expressed in mg/dl. Serum and urinary creatinine: Determined by colorimetric methods, picric acid, Taussky and Bonsness (Labtest®). The results were expressed in mg/dl. Serum and urinary Sodium and potassium (PNa+ e PK+): Determined by photometry technique with spectrophotometry, model B462 MICRONAL (Instrumentation Laboratory, Inc. USA). The results were expressed in mEq/L. Albumin: Determined by bromocresol reaction (Labtest®). The results were expressed in g/dl. Globulin: Determined by bromocresol reaction (Labtest®). The results were expressed in g/dl. Glucose: Determined by colorimetric glucose oxidase method (Labtest®). The results were expressed in mg/dl. Alkaline phosphatase: Determined by phosphatase kinetic method, Bowers and Mc Comb modified (Labtest®). The results were expressed in U/L. Amilase: Determined by colorimetric Caraway modified method. Results expressed in U/dl. pH, bicarbonate (HCO3-): were determined through “Blood gas analyser” machine (chiron diagnostic 238 - Bayer®). The results were expressed in mEq/L for bicarbonate. Urinary pH (UpH): measured by pHmetro Digital pG1000, model GEHAKALT. Urinary osmolarity: Determined by the technique pressure steam in osmometer model 5100 C (Wescor Inc., USA). The results were expressed in mOsm/Kg.H2O. Microalbuminuria: measured through immunoturbidimetry methods, using Tina-quant® kit (Roche) and the results were expressed in mcg/g creatinine.
All quantitative data are expressed as mean ± SEM. Differences between two parameters were analyzed either by paired Student t test or by nonparametric methods (Wilcoxon test and Mann–Whitney test). Chi-square test was used to analyze categoricalvariables. Values of P < 0.05 were considered statistically significant.
Clinical and demographic data of patients with ACL compared with healthy subjects
ACL (n = 37)
Control (n = 10)
35.6 ± 12
32.3 ± 11.7
Time of disease (days)
28.5 ± 20.6
Montenegro skin test (+/−)
Number of skin lesions
2 to 4
Systolic blood pressure, mmHg
117 ± 9.5
Diastolic blood pressure, mmHg
80 ± 4.7
75 ± 8.5
Montenegro skin test was positive in 59.5% of cases. All patients have ACL in its isolated cutaneous type, 27 had a solitary skin lesion, 7 had 2–4 lesions and 3 had more than 4 lesions. The mean time of disease was 28.5 ± 20.6 days (range 7–90 days).
Laboratory data of 37 patients with ACL before and after specific treatment
42.6 ± 4.1
40.5 ± 4.2
13.9 ± 1.2
13.3 ± 1.5
White blood count (/mm 3 )
6.359 ± 1918
6.035 ± 1513
Platelets (/mm 3 )
275.351 ± 66.259
292.702 ± 60.570
7.35 ± 0.1
7.35 ± 0.1
Fasting glucose (mg/dl)
80 ± 15
80 ± 17
143 ± 48
148 ± 62
Total Bilirubin (mg/dl)
0.5 ± 0.27
0.6 ± 0.23
Alkaline Phosphatase (U/L)
93 ± 33
107 ± 52
4 ± 0.6
4 ± 0.6
3.3 ± 0.86
3.3 ± 0.7
34 ± 15
46 ± 36
28 ± 19
42 ± 33
30 ± 21
26 ± 18
Glomerular and tubular function of 37 patients with ACL before and after specific treatment
Pre-glucantime (N = 37)
Post-glucantime (N = 37)
Control (N = 10)
P creat , (mg/dl)
0.81 ± 0.16
0.81 ± 0.15
0.85 ± 0.18
CrCl (ml/min/1.73 m 2 )
109.6 ± 31.5
108.4 ± 28.5
116.4 ± 22.7
U/P osm T4
2.19 ± 0.73
1.95 ± 0.73
3.47 ± 0.33
U pH T4
5.45 ± 0.64
5.19 ± 0.60*
4.82 ± 0.20 #
U osm T4
618 ± 202
552 ± 210
965 ± 81 #
1.15 ± 0.74
1.35 ± 1.51**
0.73 ± 0.39
10 ± 6.6
10.1 ± 7.6
7.50 ± 2.8#
1.07 ± 0.72
1.32 ± 1.01
0.62 ± 0.34#
10.9 ± 9.98
10.9 ± 15.7
9.10 ± 6.4
1.81 ± 1.70
1.90 ± 1.44
0.90 ± 0.40#
Microalbuminuria (mg/g creatinine)
23.6 ± 26***
14.6 ± 18.9
6.12 ± 4.06
Prevalence of renal dysfunction in 37 patients with ACL before and after specific treatment
P creat >1.2 mg/dl
CrCl <90 ml/min/1.73 m 2
Microalbuminuria > 30 mg/g creat
U osm T4 < 700mmOsm/kg H 2 O
U/P osm T4 < 2.8
U pH T4 > 5.5
EF Na+ > 2%
EF k+ > 10%
EF Ca++ > 3%
2 ( 5%)
EF PO4- > 10%
EF Mg++ > 6%
None of the patients presented severe adverse reactions to the pentavalent antimonial. Among the 37 studied cases, 5 (13.5%) presented low degree fever, myalgia and asthenia, and one patient had arthralgia and headache.
The results of the present study evidence the occurrence of asymptomatic tubular dysfunction probably induced by ACL and that partially improved after specific treatment.
All patients studied had ulcerated lesions. They were in very early stages of the disease, however they presented systemic inflammatory reactions, such as fever, arthralgias and myalgias, which have been previously reported . This can lead to humoral activation, which can explain the finding of renal tubular dysfunction.
In the present study, the number of patients with ClCr < 90 ml/min/1.73 m2 did not present significant difference before and after treatment with pentavalent antimonial (11 among 37 before treatment and 12 among 37 after treatment). Previous reports on the renal involvement in ACL have linked renal abnormalities to the use of these drugs, as acute kidney injury by tubulointerstitial nephritis or reaction Jarish-Herxheimer like, which is not in accordance to our findings [12, 15].
Renal dysfunction in visceral leishmaniasis (kala-azar) has been described [7–10, 18]. Lima Verde et al  in a study with 50 patients with kala-azar found GFR < 80 ml/min/1.73 m2 in 14 cases (28%). In another study, including 224 patients with kala-azar, acute kidney injury was found in 76 cases (33.9%) and this complication was associated with increased mortality . In a recent study by Daher et al , renal tubular dysfunction in kala-azar significantly improved after treatment with pentavalent antimonial. After specific treatment, all patients in the present study still remained with urinary concentrating and two-thirds improved previous acidification defects, suggesting that the tubular damage can be irreversible.
In our study microalbuminuria higher than 30 mg/g was found in 35% of patients before treatment and in only 8% after treatment, suggesting that glomerular lesion in ACL could have been caused by the parasitic disease per se, but without GFR reduction. In a study with 11 patients with kala-azar, 8 presented increased microalbuminuria (81.8%), which is higher than that found in ACL . Elnojomi et al  detected abnormal microalbuminuria in 35 out of 88 (40%) patients with kala-azar, with no glomerular dysfunction. Microalbuminuria can also be found in other infectious diseases that affect the skin and nerves, such as leprosy. Oliveira et al  identified microalbuminuria in 4 out of 59 patients with multibacillary leprosy (8.5%). A higher prevalence of microalbuminuria was found in another study involving leprosy patients. Kirsztajn et al . identified microalbuminuria higher than 20 mg/l in 15.8% of 96 patients with leprosy. In the present study we observed a decrease in microalbuminuria after treatment, which suggests that ACL per se can lead to increased urinary albumin loss. However microalbuminuria is not yet a well defined marker of glomerular dysfunction in infectious diseases.
In the present study, the urinary concentrating ability was evaluated by the ratio U/Posm and Uosm, measured after 12 h water deprivation and fasting, which was sensitized by the administration of DDAVP. Urinary concentration deficit was found in 27 cases (77%) before treatment and in 31 (88%) after treatment (p = 0.344). There was also no significant difference in the values of Uosm after the administration of DDAVP before and after treatment (p = 0.508). Based on these findings we can suggest that ACL per se can cause urinary concentrating deficit. The specific treatment did not improve this abnormality, but do not allow a worsening in the tubular lesion.
In a study involving 11 patients with ACL treated with pentavalent antimonial, 40 mg/kg for 30 days, the persisting urinary concentrating deficit was observed in 8 cases (72.7%) . Veiga et al , reported 5 cases of ACL treated with pentavalent antimonial in conventional doses, but with a longer duration, which developed urinary concentrating inability. Lima Verde et al , found 68% of urinary concentrating capacity defect in patients with kala-azar before pentavalent antimonial therapy. The persistence of this abnormality can be a consequence of ACL itself, which can cause a severe tubular damage. Further investigations, with a longer period of observation after ACL treatment, would be important to establish the long-term outcomes regarding this complication. Maybe urinary concentrating ability can be restored with time in this group of patients.
In the present study urinary acidification defect was found in 40% of the patients before treatment and in 16% after treatment, which suggests an important improvement in acidification ability after specific treatment for ACL. Urinary acidification deficit is less common than concentration deficit. In a study with patients with kala-azar, urinary acidification defect was found in 64% of cases after specific treatment .
Renal abnormalities detected in ACL improve partially after specific treatment, especially microalbuminuria and urinary acidification. The persistent urinary concentranting deficit may be related to a permanent damage induced by ACL or maybe an overlap effect of the treatment and the disease. Further studies are required to better understand the mechanisms involved in tubular dysfunction caused by ACL and by the treatment.
This research was supported by the Brazilian National Council for Scientific and Technological Development (CNPq). The desmopressin acetate was provided by Ferring of Brazil.
- Goto H, Lindoso JAL: Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 2010, 8: 419-433. 10.1586/eri.10.19.View ArticlePubMedGoogle Scholar
- Barral B, Pedral-Sampaio D, Grimaldi G, Momen H, Mc Mahon-Pratt D, Ribeiro de Jesus A, Almeida R, Badaró R, Barral-Neto M, Carvalho EM, Johnson WD: Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg. 1991, 44: 536-546.PubMedGoogle Scholar
- Grimaldi G, Mc-Mahon-Pratt D, Sun T: Leishmaniasis and its etiologic agents in the New World: an overview. Prog Clin Parasitol. 1991, 2: 73-118.PubMedGoogle Scholar
- Gontijo B, Carvalho MLR: Leishmaniose Tegumentar Americana. Rev Soc Bras Med Trop. 2003, 36: 71-80.View ArticlePubMedGoogle Scholar
- Desjeux P: Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004, 27: 305-318. 10.1016/j.cimid.2004.03.004.View ArticlePubMedGoogle Scholar
- Roberts LJ, Handeman E, Foote SJ: Leishmaniasis. Br Med J. 2000, 321: 801-804. 10.1136/bmj.321.7264.801.View ArticleGoogle Scholar
- Salgado-Filho N, Ferreira TM, Costa JM: Envolvimento da função renal em pacientes com leishmaniose visceral (calazar). Rev Soc Bras Med Trop. 2003, 36: 217-221. 10.1590/S0037-86822003000200004.View ArticlePubMedGoogle Scholar
- Chaigne V, Knefati Y, Lafarge R, Bronner J, MC Gregor B, Fouque B, Sabatier JC: A patient with visceral leishmaniasis and acute renal failure in necrotizing glomerulonephritis. Nephrologie. 2004, 25: 179-183.PubMedGoogle Scholar
- Duvic C, Nedelec G, Debord T, Herody M, Didelot F: Important parasitic nephropathies: update from recent literature. Nephrologie. 1999, 20: 65-74.PubMedGoogle Scholar
- Oliveira MJC, Silva Júnior GB, Abreu KLS, Rocha NA, Garcia AVV, Franco LFLG, Mota RMS, Libório AB, Daher EF: Risk factors for acute kidney injury in visceral leishmaniasis. Am J Trop Med Hyg. 2010, 83: 449-453. 10.4269/ajtmh.2010.10-0313.View ArticleGoogle Scholar
- Councilman WT: Acute interstitial nephritis. J Experiment Med. 1988, 3: 393-420.View ArticleGoogle Scholar
- Cucé LC, Belda J, Dias W: Nephrotoxicyty to Glucantime® in the treatment of leishmaniasis. Rev Inst Med Trop S Paulo. 1990, 32: 249-251. 10.1590/S0036-46651990000400003.View ArticlePubMedGoogle Scholar
- Duarte MIS, Silva MRR, Gotto H, Nicodemo EL, Amato-Neto V: Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg. 1983, 77: 531-537. 10.1016/0035-9203(83)90131-1.View ArticlePubMedGoogle Scholar
- Lima Verde EM, Lima Verde FAA, Lima Verde FA, Silva Júnior GB, Daher EF: Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol. 2007, 20: 432-438.Google Scholar
- Rodrigues MLO, Costa RS, Souza CS, Fossi NT, Roselino AMF: Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop S Paulo. 1999, 41: 33-37. 10.1590/S0036-46651999000100007.View ArticlePubMedGoogle Scholar
- Oliveira RA, Diniz LFB, Teotonio LO, et al: Renal tubular dysfunction in patients with American cutaneous leishmaniasis. Kidney Int. 2011, 80: 1099-1106. 10.1038/ki.2011.251.View ArticlePubMedGoogle Scholar
- Abadir A, Patel A, Haider S: Systemic therapy of new world cutaneous leishmaniasis: a case report and review article. Can J Infect Dis Med Microbiol. 2010, 21: e79-e83.PubMedPubMed CentralGoogle Scholar
- Dutra M, Martinelli R, de Carvalho EM, et al: Renal involvement in visceral leishmaniasis. Am J Kidney Dis. 1985, 6: 22-27.View ArticlePubMedGoogle Scholar
- Daher EF, Rocha NA, Oliveira MJ, Franco LF, Oliveira JL, Silva Junior GB, Abreu KL, Henn GA, Martins AM, Libório AB: Renal function improvement with pentavalent antimonial agents in patients with visceral leishmaniasis. Am J Nephrol. 2011, 33: 332-336. 10.1159/000324914.View ArticlePubMedGoogle Scholar
- Elnojomi N, Musa AM, Younis BM, Elfaki M, EL-Hassan AM, Khalil E: Surrogate markers of subtle renal injury in patients with visceral leishmaniasis. Saudi J Kidney Dis Transpl. 2010, 21: 872-875.PubMedGoogle Scholar
- Oliveira RA, Silva GB, Souza CJ, et al: Evaluation of renal function in leprosy: a study of 59 consecutive patients. Nephrol Dial Transplant. 2008, 23: 256-262.View ArticlePubMedGoogle Scholar
- Kirsztajn GM, Nishida SK, Silva MS, Ajzen H, Pereira AB: Renal abnormalities in Leprosy. Nephron. 1993, 65: 381-384. 10.1159/000187517.View ArticlePubMedGoogle Scholar
- Sampaio RNR, Paula CDR, Sampaio JHD, Furtado RS, Leal PP, Rosa TT, Rodrigues MR, Veiga JPR: Avaliação da tolerância e nefrotoxicidade do antimonial pentavalente administrado na dose de 40 mg Sbv/kg/dia por 30 dias na forma cutânea-mucosa de leishmaniose. Rev Soc Bras Med Trop. 1997, 30: 457-467. 10.1590/S0037-86821997000600003.View ArticlePubMedGoogle Scholar
- Veiga JPR, Khanan R, Rosa TT, Junqueira LF, Brant PC, Raick AN, Friedman H, Marsden PD: Pentavalent antimonial nephrotoxicity in the rat. Rev Inst Med Trop S Paulo. 1990, 32: 304-309. 10.1590/S0036-46651990000400012.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/13/44/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.